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SUMMARY
In late mitosis and G1, origins of DNA replication
must be ‘‘licensed’’ for use in the upcoming S phase
by being encircled by double hexamers of the
minichromosome maintenance proteins MCM2–7. A
‘‘licensing checkpoint’’ delays cells in G1 until suffi-
cient origins have been licensed, but this checkpoint
is lost in cancer cells. Inhibition of licensing can
therefore kill cancer cells while only delaying normal
cells in G1. In a high-throughput cell-based screen for
licensing inhibitors we identified a family of 2-aryl-
quinolin-4-amines, the most potent of which we call
RL5a. The binding of the origin recognition complex
(ORC) to origin DNA is the first step of the licensing
reaction. We show that RL5a prevents ORC forming
a tight complex with DNA that is required for
MCM2–7 loading. Formation of this ORC-DNA com-
plex requires ATP, and we show that RL5a inhibits
ORC allosterically to mimic a lack of ATP.
INTRODUCTION
During S phase of the eukaryotic cell division cycle, pairs of
replication forks are initiated at replication origins distributed
throughout the genome. These replication origins must be regu-
lated so that during each cell cycle no sections of DNA are
left unreplicated and no sections of DNA are replicated more
than once. Eukaryotes achieve this by dividing the replication
process into two non-overlapping phases. During late mitosis
and early G1, replication origins are ‘‘licensed’’ for future use by
being loaded with double hexamers of the MCM2–7 proteins
(Blow and Dutta, 2005; Arias and Walter, 2007). Each MCM2–7
hexamer forms a ring with a positively charged central channel.
In the licensing reaction, the MCM2–7 hexamers are clamped
around double-stranded DNA (Evrin et al., 2009; Remus et al.,
2009; Gambus et al., 2011). During S phase, the Cdc45 and
GINS proteins associate with the MCM2–7 double hexamers
to form the replicativeCMG (Cdc45-MCM-GINS) helicase (Moyer
et al., 2006; Ilves et al., 2010). Since the ability to license repli-
cation origins ceases before cells enter S phase, MCM2–7 hex-
amers are exclusively associatedwith unreplicatedDNA, thereby
preventing re-replicationofDNA (BlowandDutta, 2005;Arias and
Walter, 2007).
However, individual forks can irreversibly stall before termina-
tion. This can be caused by forks encountering DNA damage or
tightly associated DNA-protein complexes, or by fork movement
being slowed by replication inhibitors (Lambert and Carr, 2005).
If two converging replication forks irreversibly stall, there is no
simple way for the cell to replicate the intervening DNA. Cells
cannot load new MCM2–7 hexamers onto the DNA between
the two stalled forks, as this would also allow the reloading of
MCM2–7 onto replicated DNA, leading to re-replication. Cells
protect themselves from the consequences of irreversible fork
stalling by licensing an oversufficiency of replication origins, not
all ofwhich are used in anygivenSphase,with themajority instead
remaining dormant (Woodward et al., 2006; Ge et al., 2007; Ibarra
et al., 2008; Blow and Ge, 2009; Ge and Blow, 2010; Blow
et al., 2011).
Because there is no opportunity to license new origins
once cells have entered S phase, it is critical that cells exit G1
only when they have licensed a sufficient number of origins.
To enforce this many cells possess a ‘‘licensing checkpoint’’
that delays progression out of G1 until enough origins have
been licensed (Shreeram et al., 2002; Feng et al., 2003; Montag-
noli et al., 2004; Machida et al., 2005; Teer et al., 2006; Liu et al.,
2009; Blow and Gillespie, 2008; Nevis et al., 2009). It is currently
unclear precisely how the licensing checkpoint assesses the
number of licensed origins. When the checkpoint is engaged it
suppresses CDK activity that is required for cells to progress
out of G1 into S phase (Shreeram et al., 2002; Machida et al.,
2005; Teer et al., 2006; Liu et al., 2009; Nevis et al., 2009).
This downregulation of CDK activity likely occurs by several
mechanisms, including suppression of cyclin D1 transcription
(Liu et al., 2009), decreased levels of cyclin E (Shreeram et al.,
2002; Teer et al., 2006), inhibition of essential CDK2 phosphory-
lation on threonine 160 (Nevis et al., 2009), and the activation of
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p53 and the CDK inhibitors p21Cip1 and p27Kip1 (Liu et al., 2009;
Machida et al., 2005; Nevis et al., 2009; Teer et al., 2006). This
reduction in G1 CDK levels prevents the hyperphosphoryla-
tion of the pRb transcriptional repressor, thereby blocking the
transcriptional program required for cells to enter S phase.
This leaves the cells at a stage of G1 where the licensing system
is still active.
Importantly, the licensing checkpoint is defective in many
cancer cells, perhaps due to the involvement of p53, Rb, and
p21Cip1, which are mutated or ineffective in many cancers
(Shreeram et al., 2002; Feng et al., 2003; Montagnoli et al.,
2004; Liu et al., 2009; Nevis et al., 2009; Blow and Gillespie,
2008). This makes the licensing system an attractive anti-cancer
target with a potentially high therapeutic index for many different
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Figure 1. A Cell-Based Screen for Licensing
Inhibitors
(A) Asynchronous U2OS cells were pulsed with
EdU for 30 min, then labeled for EdU incorpora-
tion, chromatin-bound MCM2, and total DNA, and
analyzed by flow cytometry. For the plot, G1 cells
(G1 DNA content, EdU negative) were colored
red, S-phase cells (EdU positive) were colored
blue, and G2 cells (G2 DNA content, EdU negative)
were colored orange, and then plotted for total
DNA content and chromatin-bound MCM2.
(B) Outline of the protocol for assaying potential
licensing inhibitors.
(C and D) Immunofluorescence images of cells
after the RO3306 block (C) or 8 hr later at the end
of the assay (D) immunostained for MCM4 (green)
and with DAPI for DNA (blue). Scale bar, 10 mm.
(E) Cartoon of possible outcomes of the screen
derived from total cellular DNA content and amount
of chromatin-bound MCM2–7.
(F) Examples of output from the cell-based screen:
(i) late S/G2 enriched starting cells; (ii) non-specific
inhibition, showing G2 accumulation; (iii) no inhibi-
tion, showing licensed G1 cells; (iv) hit compound
showing unlicensed G1 cells.
See also Figures S1 and S6.
sorts of cancers. Normal cells treated with
licensing inhibitors should engage the
licensing checkpoint and arrest in G1,
capable of completing licensing when
the inhibitor is withdrawn; in contrast,
cancer cells lacking the licensing check-
point will enter S phasewith an insufficient
number of licensed origins, a situation that
is almost certainly lethal (Blow and Gilles-
pie, 2008).
In this article we describe a cell-based
screen for small-molecule inhibitors of the
replication licensing system inhumancells.
This led to the identification of a related
chemical family of 2-arylquinolin-4-amines
that we call RL5, which inhibits licensing
both in human tissue culture cells and in
biochemically tractable Xenopus egg ex-
tracts.Weshow thatRL5a, themostpotent
of these compounds identified to date, prevents the tight associ-
ation of ORC with DNA that is required for replication licensing
to occur. ORC binding to DNA requires ATP, but ATP titration
shows that RL5a acts non-competitively with respect to ATP.
RESULTS
A High-Throughput Cell-Based Screen for Licensing
Inhibitors
We have recently devised a 3-dimensional (3D) fluorescence-
activated cell sorting (FACS) assay to simultaneously measure
the loading of MCM2–7 onto chromatin, 5-ethynyl-20-deoxyuri-
dine (EdU) incorporation (as a measure of DNA synthesis), and
cellular DNA content (Moreno et al., 2016). Figure 1A shows a
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2Dplot of these data, with chromatin-boundMCM2on the y axis,
DNA content on the x axis, and information from EdU incorpora-
tion color coded (G1 red, S phase blue, G2 orange). At cytoki-
nesis, newborn daughter cells have a 2N DNA content with low
levels of DNA-bound MCM2. During G1 MCM2 is loaded onto
DNA until it reaches a maximum, which likely represents cells
satisfying the ‘‘licensing checkpoint.’’ MCM2 is progressively
displaced as DNA is replicated during S phase, until DNA-bound
MCM2 falls to background levels in G2.
We used these changes to design a high-throughput assay for
licensing inhibitors (Figure 1B). HumanU2OS cells were released
into S phase from a double-thymidine block (Figures S1A–S1C)
and then treated with RO3306, a CDK1 inhibitor, to reversibly
block them in G2 (Figure S1D). RO3306 was removed and cells
were seeded into 384-well plates containing test compounds
(Figure S1E). Eight hours later, when cells should have passed
through mitosis and loaded MCM2–7, cells were fixed and
immunostained for DNA-bound MCM4 and also treated with
DAPI to stain total DNA (Figure S1F). Microscopic images of
each treatment (Figures 1C and 1D) were taken on an InCell
1000 system, which returned values for MCM4 and DNA content
for each of the cells identified.
Figure 1E shows a schematic of possible outcomes of this pro-
cedure, and Figure 1F shows some example results from the
A B
C D
E
Percentage inhibition of MCM4 loading
Figure 2. Licensing Assays in Human and
Xenopus Systems
(A) Percentage inhibition of MCM4 loading
observed with all 24,000 compounds in the initial
screen.
(B) Validated hits from the primary and secondary
screen in U2OS cells were assayed for their ability
to inhibit an in vitro licensing assay in Xenopus egg
extracts. The degree of licensing is expressed as a
percentage of that observed in control ‘‘Licensing
Factor’’ extract.
(C) Immunoblot of total and chromatin-bound
MCM2, MCM3, and MCM5 in U2OS cells treated
with either RL5a or DMSO.
(D) Immunoblot of chromatin-bound MCM7 from
Xenopus ‘‘Licensing Factor’’ extract treated with
DMSO, geminin, RL5a, RL5b, or RL5c.
(E) Structures of RL5a–e.
See also Figures S2 and S6.
screen. At the time of addition of test
compounds, cells had low levels of
DNA-boundMCM4 and a G2 DNA content
(Figure 1E, white circle). Cells essentially
unaffected by test compounds then
passed through mitosis to acquire a
G1 DNA content and high levels of DNA-
bound MCM4 (Figure 1E, green circle;
Figure 1Fiii, ‘‘no effect’’). When exposed
to compounds that specifically inhibit
licensing, cells passed through mitosis
into G1 without acquiring high levels of
DNA-bound MCM4 (Figure 1E, red circle;
Figure 1Fiv, ‘‘hit’’). When exposed to
compounds that cause non-specific inhi-
bition of essential cellular functions, cells failed to pass through
mitosis and maintained a G2 DNA content (Figure 1E, white cir-
cle; Figure 1Fii, ‘‘non-specific’’).
The 24,000 small-molecule compound collection held by
the Drug Discovery Unit at the University of Dundee was tested
at 200 mM. The screen performance indicators were signal to
background 2.4 ± 0.53 and Z-prime 0.47 ± 0.10. Figure 2A shows
the frequency distribution of inhibition of loading of MCM4
that was obtained. There was an approximately normal distri-
bution but with a shoulder between 70% and 130%, indicating
the presence of a subpopulation of hits, which do not fit to the ex-
pectednormaldistributionpopulation.Hit compoundsareusually
defined by a statistical cutoff of mean ± 3 SDs, which in this
case are represented by the 349 compounds that gaveR96.72
percentage inhibition. To minimize the chance of excluding
true-positive compounds, we decided to focus on the com-
pounds in the shoulder, and adjusted the initial cutoff value to
70%, resulting in progression of 929 compounds for retesting
in duplicate. A total of 280 compounds demonstrated R60%
inhibition in both replicates (30.1% confirmation rate).
To avoid any confounding effects of RO3306 treatment, we
then retested these 280 compounds using a low-throughput
screen whereby cells were synchronized by mitotic shake-off
prior to exposure with test compounds. This low-throughput
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assay also has the advantage of removing cells that suffer non-
specific inhibition by test compounds, as only metabolically
active cells can re-adhere to the plates. Sixteen compounds pro-
duced a reproducible reduction (>60%) of DNA-bound MCM4
in this assay. These 16 compounds fell into eight discrete chem-
ical families, which we named RL1 to RL8. After resynthesis and
re-assay, we decided to take 12 of these 16 compounds forward
for further study: RL1a, RL1b, RL2, RL3a, RL3b, RL4, RL5a–
RL5e, and RL8. Figure S2 shows titration curves for these 12
compounds.
We next aimed to distinguish compounds that directly inhibit
replication licensing from compounds that have secondary
effects indirectly inhibiting licensing. To do this we used a cell-
free system from Xenopus (frog) eggs that supports efficient
replication licensing in vitro (Blow and Laskey, 1988; Blow,
1993; Chong et al., 1995). This system has been reconstituted
with purified proteins and is fairly well understood biochemically
(Gillespie et al., 2001). The system also shows strong comple-
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Figure 3. Activity of RL5a in Whole Xenopus
Egg Extract
(A) Sperm nuclei were incubated in whole Xenopus
egg extract supplemented with 25, 50, 100, 150
or 200 mM RL5a, DMSO, or geminin. After 20 min
chromatin was isolated and immunoblotted for
MCM3 or stained with Coomassie to show his-
tones.
(B) MCM3 chromatin association in (A) was quan-
tified relative to control (mean ± SEM, n = 4).
(C and D) Sperm nuclei were incubated in whole
Xenopus egg extract supplemented with [a-32P]
dATP. At either the time of DNA addition (C) or
20 min later (D), extract was additionally supple-
mented with 0, 25, 50, 100, 150, or 200 mMRL5a in
DMSO. At the indicated times, the total amount of
DNA synthesized was determined by trichloro-
acetic acid precipitation and scintillation counting.
(E) Sperm nuclei were incubated in whole egg
extract supplemented with DMSO or 200 mMRL5a.
At the indicated times nuclear formation was
assessed by either (i) phase contrast or (ii) UV
microscopy. Scale bar, 20 mm.
See also Figures S3 and S4.
mentarity with the equivalent reaction
taking place in mammalian cells, as the
proteins required for licensing in the
Xenopus system (Gillespie et al., 2001)
can be substituted by equivalents from
mammalian cells (Vashee et al., 2003; Sa-
saki et al., 2011). In the licensing assay,
the selected compounds gave varying
degrees of inhibition (Figure 2B); most
striking was the behavior of the RL5
family, three members of which (RL5a, b,
and c), but not the highly related RL5d,
showed very strong inhibition. RL5a, b,
c, and d belong to a family of 2-arylqui-
nolin-4-amines, and their chemical struc-
tures, together with that of the related
RL5e, are shown in Figure 2E. It should
be noted that the failure of other compounds in this assay might
be due to differences in the exact amino acid sequences of the
human and Xenopus homologs of the licensing proteins.
We next used chromatin isolation and immunoblotting
to directly show that, as expected from our functional assays,
RL5 compounds prevented the loading of MCM2–7 proteins
onto DNA in human U2OS cells (Figure 2C) and Xenopus egg
extracts (Figure 2D). Because of its slightly higher potency, we
concentrate on the activity of RL5a in the rest of this article (Fig-
ures 2B and S2).
We next examined the activity of RL5a in whole Xenopus
egg extract to determine the potency for inhibition of replica-
tion licensing relative to other non-specific effects. RL5a was
titrated into interphase egg extract, sperm nuclei were added
as template DNA, and the ability for MCM2–7 to be loaded
onto DNA was quantified by isolating chromatin and immuno-
blotting for MCM3 (Figures 3A and 3B). Geminin, a small protein
inhibitor of replication licensing (McGarry and Kirschner, 1998;
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Wohlschlegel et al., 2000; Tada et al., 2001), was used as a
control. Figures 3A and 3B show a relatively smooth dose-
response curve, with 200 mM RL5a almost completely blocking
MCM3 loading. In parallel, we assayed the ability of RL5a to
block DNA replication.
There is a complex relationship between the inhibition of MCM
loading and inhibition of replication. Previous results in Xenopus
showed that when licensing was partially inhibited with geminin
so that MCM loading was reduced by 90% bulk DNA replica-
tion was only slightly inhibited, but when MCM loading was
further reduced the rate of DNA synthesis dropped sharply
(Woodward et al., 2006). Figure 3C shows that 25 and 50 mM
RL5a had a negligible effect on replication, but 100, 150, and
200 mM showed extensive inhibition. The effect of RL5a shown
in Figures 3B and 3C is consistent with RL5a primarily inhibiting
replication by inhibition of licensing, but also suggests additional
non-specific inhibition of replication.
To obtain an idea of how specific the inhibition of RL5a is to
replication licensing, we modified the replication assay: instead
of adding RL5a at the start of the incubation, we added DNA to
the extract and then added RL5a 20 min later. Within this first
20-min period all origins become licensed in the egg extract,
and subsequent inhibition of the licensing system has no effect
on DNA replication (Gillespie and Hirano, 2004; Oehlmann
et al., 2004; Woodward et al., 2006). However, after 20 min
the extract still needs to assemble template DNA into functional
interphase nuclei, import nuclear proteins, activate DDK and
CDK kinases, initiate replication forks at licensed origins, and
perform the elongation stage of DNA replication (Blow and Wat-
son, 1987; Newport, 1987; Sheehan et al., 1988; Blow and
Sleeman, 1990; Cox, 1992). Therefore, inhibition of DNA syn-
thesis by RL5a added at 20 min reflects inhibition of these other
processes and thus gives an indication of its specificity as a
licensing inhibitor. Figure 3D shows that when added 20 min
after the template DNA, 200 mM RL5a caused only a modest
inhibition of subsequent DNA replication while 150 mM RL5a
had no significant effect (Figure 3D). Consistent with this inter-
pretation, Figure 3E shows that even when 200 mM RL5a is
added at the start of the incubation, nuclei form normally.
Furthermore, when chromatin was isolated from Xenopus egg
extract at various times and total protein content was analyzed
by SDS-PAGE, RL5a caused very little difference in the loading
of proteins other than MCM2–7 onto chromatin (Figure S3). We
therefore conclude that RL5a has a fair degree of selectivity
for inhibiting replication licensing, but also has some inhibitory
activity against other cellular activities required for DNA repli-
cation. Consistent with this, when 10 mM RL5a was added to
U2OS cells following release from a double-thymidine syn-
chronization, it delayed passage through S phase even though
no further licensing occurs at this stage of the cell cycle
(Figure S4).
RL5a Prevents ORC Forming a Tight Complex with DNA
The licensing of DNA occurs in a multistep reaction that requires
aminimumof four proteins: ORC, Cdc6, Cdt1, andMCM2–7 (Gil-
lespie et al., 2001; Evrin et al., 2009; Remus et al., 2009). The pro-
cess, which is outlined in Figure 4A, also involves the hydrolysis
of ATP and results in double hexamers of MCM2–7 being wrap-
ped around double-stranded DNA (Chong et al., 1995; Gillespie
et al., 2001; Evrin et al., 2009; Remus et al., 2009; Gambus et al.,
2011). Since this is an energy-dependent reaction, we first asked
whether RL5a blocked the loading of MCM2–7 onto DNA or
whether it could also promote the unloading of MCM2–7 that
was already bound to DNA.When added to Xenopus egg extract
before template DNA, RL5a efficiently inhibited MCM3 loading
onto DNA, consistent with previous assays (Figure 4B, ‘‘unli-
censed DNA’’). However, when MCM2–7 was allowed to load
onto DNA and RL5a was added afterward, MCM3 remained
bound to DNA (Figure 4B, ‘‘pre-licensed DNA’’). We conclude
that RL5a prevents the loading of MCM2–7 onto DNA but
does not significantly promote the unloading of DNA-bound
MCM2–7. This is consistent with the experiment shown in Fig-
ure 3D, where DNA replication still occurred when RL5a was
added to extract 20 min after template DNA.
A
B pre-licensed DNAunlicensed DNA
MCM3
Cdc6
Orc1
Orc2
Histones
RL5a (μM)0 200100 0 200100
ORC
ORC
Cdc6 Cdt1
M
ORC
Cdc6 Cdt1
Figure 4. Effect of RL5a on Unlicensed and Pre-licensed DNA
(A) Cartoon of the sequential loading of ORC, Cdc6, Cdt1, and MCM2–7 onto
origin DNA.
(B) Sperm nuclei were incubated in Xenopus egg extract. At the time of DNA
addition (‘‘unlicensed DNA’’) or 15 min later (pre-licensed DNA), extract was
optionally supplemented with geminin, DMSO, or the indicated concentrations
of RL5a. After a further 20 min, chromatin was isolated and immunoblotted for
ORC subunits (Orc1 and Orc2), Cdc6, and MCM3. The bottom of the gel was
stained with Coomassie to show histones.
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We next investigated the stage of the licensing reaction that
is inhibited by RL5a. Figure 4B shows that when extract was
treated with RL5a, ORC (both the Orc1 and Orc2 subunits) and
Cdc6 still bound to DNA. As will become important for the
interpretation of subsequent experiments, RL5a did not pre-
vent the association of ORC or Cdc6 with DNA that had already
been licensed (Figure 4B, ‘‘pre-licensed DNA’’). Assays to mea-
sure Cdt1 binding are complicated by the relative insolubility of
Cdt1 (Tada et al., 2001) and its requirement for ATP in the binding
reaction (Evrin et al., 2013; Randell et al., 2006; Remus et al.,
2009). We therefore first concentrated on determining any
possible effect of RL5a on ORC and Cdc6.
It has previously been shown, in Xenopus egg extract,
Saccharomyces cerevisiae, and Caenorhabditis elegans early
embryos, that the affinity of ORC and Cdc6 for DNA differs de-
pending on whether or not the DNA is licensed (Rowles et al.,
1999; Oehlmann et al., 2004; Tsakraklides and Bell, 2010;
Sonneville et al., 2012). Before licensing has occurred, ORC
and Cdc6 bind to DNA relatively tightly, but this binding is
significantly loosened once origins have been licensed. This
behavior is shown in Figure 5, where chromatin was isolated
from extracts supplemented with either RL5a or DMSO control
and exposed to 50, 100, or 200 mM KCl. Example immunoblots
for chromatin-bound ORC (the Orc1 subunit) and Cdc6 are
shown in Figure 5A, and the levels of Orc1 and Cdc6 in repli-
cate experiments are plotted in Figure 5B. In control extracts
treated with DMSO, where origin licensing does not occur,
both ORC and Cdc6 were present on chromatin treated with
50 mM KCl but were removed by higher KCl concentrations:
most of the Cdc6 and approximately half the ORC was removed
in 100 mM KCl, and neither protein was abundant on chromatin
treated with 200 mM KCl. When licensing was blocked, either
by the Cdt1 inhibitor geminin or by depletion of MCM3 or
Cdc6, the amount of ORC and Cdc6 remaining on chromatin
at 100 and 200 mM KCl was significantly increased, indicating
their tight binding to DNA before licensing has occurred (Rowles
et al., 1999; Oehlmann et al., 2004; Sonneville et al., 2012).
Since RL5a blocks licensing, we might expect it to promote
the tight binding of ORC and Cdc6 to DNA that is resistant to
high salt exposure. However, in extract treated with RL5a,
both ORC and Cdc6 were readily removed from DNA by 100
or 200 mM KCl. This indicates that RL5a prevents ORC and
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Figure 5. Effect of RL5a on Licensing-Defective Extracts
Sperm nuclei were incubated in Xenopus egg extract that had optionally been depleted of MCM3 or Cdc6 or which had been supplemented with geminin and
which were further supplemented with 200 mMRL5a or DMSO. After 20 min, chromatin was isolated in 50, 100, or 200 mM KCl and then immunoblotted for ORC
(Orc1 subunit) or Cdc6.
(A and B) A representative series of blots is shown in (A). Blots from at least three separate experiments were quantified for the amount of chromatin-bound ORC
(Orc1 subunit) and Cdc6. The mean signal ± SEM, relative to control chromatin isolated in 50 mM KCl, is plotted in (B).
(C) Plasmid DNA (pET28) was incubated in a partially purified fraction of ORC supplemented with 2.5 mM ATP and either 25, 50, 100, 150, or 200 mM RL5a or
DMSO. After 30 min, DNA was isolated in 100 mM KCl and then immunoblotted for Orc1 and Orc2.
(D) Orc1 and Orc2 plasmid DNA association in (C) was quantified relative to recovered DNA and expressed in relation to control (mean ± SEM, nR 5).
See also Figure S5.
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Cdc6 from forming a tight complex with DNA that normally oc-
curs before licensing takes place.
When chromatin was isolated from extract in which licensing
had been inhibited with geminin, Orc1, Orc2, and Orc3 were
discernible on SDS-PAGE gels stained for total protein (Fig-
ure S5). Under these conditions, increasing concentrations of
RL5a reduced the chromatin association of these ORC subunits
but otherwise had very little effect on the loading of proteins onto
unlicensed chromatin. Together with Figure S3, this shows that
the two major activities whose chromatin association is limited
by RL5a are MCM2–7 and ORC. Since MCM2–7 loading onto
DNA (origin licensing) is dependent on ORC, this suggests that
RL5a inhibits licensing by inhibiting the association of ORC
with DNA.
Since in these experiments we are examining the licensing of
DNA that is associated with nucleosomes formed into chro-
matin, it is possible that RL5a acts on the nucleosomes to inhibit
ORC binding (Lipford and Bell, 2001). To test this, we prepared
a partially purified fraction of Xenopus egg extracts that con-
tains ORC but is not competent to support nucleosome assem-
bly (Gillespie and Blow, 2000; Gillespie et al., 2001). Figure 5C
shows that in this partially purified fraction of ORC, RL5a inhibits
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Figure 6. ATP Requirement for ORC and
Cdc6 DNA Binding
(A) Whole Xenopus egg extract was desalted and
then supplemented with 2.5 mM ATP or ATP-g-S
plus or minus geminin. Sperm nuclei were incu-
bated in extract for 20 min and isolated in 50, 100,
or 200mMKCl, then immunoblotted for ORC (Orc1
and Orc2 subunits), Cdc6, Cdt1, and MCM3. The
bottom of the gel was stained with Coomassie to
show histones.
(B) Sperm nuclei were incubated in whole Xenopus
egg extract that had optionally been treated with
geminin, apyrase, or ATP-g-S. After 20 min, chro-
matin was isolated in 50, 100, or 200 mM KCl and
then immunoblotted for ORC (Orc1 and Orc2
subunits) and MCM3. The bottom of the gel was
stained with Coomassie to show histones.
(C and D) Sperm nuclei were incubated in whole
Xenopus egg extract that had optionally been
treated with geminin, apyrase, ATP-g-S, or RL5a.
After 20min, chromatin was isolated in 100mMKCl
and then immunoblotted for ORC (Orc1 and Orc2
subunits) and MCM3. The bottom of the gel was
stained with Coomassie to show histones.
(E and F) Xenopus egg extract was depleted of
ATP by precipitation with polyethylene glycol, then
supplemented with the indicated concentrations
of ATP plus or minus 200 mM RL5a. Sperm nuclei
were incubated in the reconstituted extract for
15 min, and the degree of licensing obtained was
determined by assaying for replication in extract
supplemented with geminin. Raw values for the
mean ± SEM of three independent experiments (E)
and a Lineweaver-Burk plot of the inverse values
(F) are shown.
ORC binding to naked plasmid DNA.
Importantly, the extent to which RL5a
restricts ORC binding to plasmid DNA
(Figure 5D) is similar to that seen on chro-
matin (Figures 5B and S5) and also matches the inhibition of
licensing by RL5a (Figures 3A and 3B). Taken together, these
results strongly suggest that RL5a inhibits licensing by directly
inhibiting the association of ORC with DNA and that this activity
is not mediated by indirect effects on chromatin.
RL5a Inhibits ORC Allosterically to Mimic a Lack of ATP
ORC and Cdc6 both have ATPase activity, and their binding
to DNA is affected by the presence of ATP (Bell and Stillman,
1992; Speck et al., 2005). We therefore investigated how RL5a
affected the ATP requirements for the binding of ORC and
Cdc6 to DNA. We used several different ways of manipulating
ATP content in Xenopus egg extracts. In the first approach,
we removed nucleotides and other small molecules from the
extract using a desalting column (Figure 6A). When template
DNA was incubated in desalted extract, ORC (Orc1 and Orc2
subunits) and Cdc6 were observed to bind to the DNA. However,
no DNA-bound Cdt1 was observed and licensing (as evidenced
by salt-sensitive MCM3 binding) did not occur. Consistent with
previous results (Chong et al., 1995; Gillespie et al., 2001),
when the desalted extract was supplemented with ATP, tem-
plate DNA was licensed and was stably loaded with MCM3. As
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a consequence of active licensing, the DNA binding of ORC and
Cdc6 was weakened. Figure 6A also shows that when extract
was supplemented with ATP-g-S, a non-hydrolyzable form of
ATP, no licensing occurred, but a small amount of MCM3 was
observed to be associated with DNA that could be removed by
high salt. This is consistent with the recruitment of MCM2–7 to
ORC and Cdc6 on DNA without the ATP-dependent clamping
of the MCM2–7 hexamer around DNA (Evrin et al., 2009; Remus
et al., 2009). ATP-g-S also caused a significant increase in the
DNA binding of ORC (Orc1 and Orc2 subunits), Cdc6, and
Cdt1. When ATP was added to the extract but licensing was in-
hibited with geminin, a similar increase in ORC and Cdc6 was
observed. These results suggest that the tightly bound form of
ORC and Cdc6 that is seen on unlicensed DNA in whole extract
(Figure 5) requires unhydrolyzed ATP.
As an alternative method for analyzing the role of ATP in the
licensing reaction and its relationship to inhibition by RL5a, we
used apyrase, an enzyme that rapidly hydrolyzes ATP to AMP
(Seki and Diffley, 2000). Figure 6B shows that extract treated
with apyrase did not load MCM3 onto chromatin, and the bind-
ing of ORC (Orc1 and Orc2 subunits) to DNA was weak and
highly salt sensitive, similar to their behavior in desalted extract.
When ATP-g-S was added to apyrase-treated extract, it caused
a significant increase in the binding of ORC to DNA, similar to the
effect of adding ATP-g-S to desalted extract. We then examined
the effect of RL5a on the binding of ORC to DNA in extracts lack-
ing hydrolyzable ATP. Figures 6C and 6D show that RL5a signif-
icantly weakened the otherwise salt-resistant binding of ORC to
DNA under conditions when licensing was blocked by geminin or
in the presence of ATP-g-S. These experiments show that RL5a
prevents the tight binding of ORC to DNA that is observed prior
to origin licensing and which requires ATP or ATP-g-S.
We therefore examined whether RL5a exerts its function
by competing with ATP for binding to ORCor whether it acts allo-
sterically. To control ATP concentration, diluted and clarified
‘‘licensing factor extract’’ (LFE) was precipitated with 16% poly-
ethylene glycol; these conditions precipitate all the proteins
required for origin licensing (ORC, Cdc6, Cdt1, and MCM2–7)
and removes the majority of ATP (Chong et al., 1995). Extract
was then resuspended in buffer containing 0.2–2 mM ATP and
used to perform a functional licensing assay, plus and minus
100 mM RL5a. The raw values are shown in Figure 6E, while Fig-
ure 6F shows the data in a double reciprocal (Lineweaver-Burk)
plot. In the absence of RL5a, the ATP titration cut the x axis of the
double reciprocal plot at approximately 1.65, suggesting that
the Michaelis-Menten constant (KM) of the reaction for ATP
is 0.6 mM. In the presence of RL5a, the slope of the double
reciprocal plot was steeper, and cut the x axis at about 1.25
(apparent KM for ATP of 0.8 mM). The similarity of the x axis
intercepts is consistent with RL5a functioning largely as a non-
competitive inhibitor with respect to ATP.
Effect of RL5a on Non-transformed Cells
The inhibition of replication licensing should allow discrimina-
tion between cells that can engage the licensing checkpoint
and those that cannot: whereas normal cells will reversibly
arrest in G1 following licensing inhibition, cancer cells lacking
the checkpoint will enter an abortive S phase. We therefore
compared the effect of a range of concentrations of RL5a
(1–100 mM) on U2OS cancer cells, which lack the checkpoint,
with the effect on checkpoint intact IMR90 primary fibroblasts
(Figure 7A). RL5a caused a strong inhibition of U2OS cell
growth, with concentrations of 2 mM and higher completely
abolishing an increase in cell number. In contrast, primary
IMR90 cells were more resistant to RL5a, proliferating to almost
normal levels in 1 mM RL5a. This suggests that there is a funda-
mental difference between the two cell types, which would be
consistent with the functioning of the licensing checkpoint in
IMR90 but not U2OS cells.
DISCUSSION
We describe a cell-based assay for small-molecule inhibitors of
the replication licensing system. Replication licensing is an
attractive anti-cancer target as normal cells possess a ‘‘licensing
checkpoint’’ that many cancer cells lack, most likely because it
requires the activity of proteins such as p53, Rb, and p21Cip1,
which are often lost in cancer. Inhibition of licensing should
therefore have a high therapeutic index, directly killing cancer
cells lacking the checkpoint, while simply delaying normal
cells in G1 phase of the cell cycle (Shreeram et al., 2002; Blow
and Gillespie, 2008). We screened 24,000 small-molecule com-
pounds for their ability to prevent the loading of MCM4 onto
chromatin in human U2OS cells. This revealed 16 compounds
in eight discrete chemical families that significantly inhibited
the licensing reaction. To determine their mode of action, these
compounds were re-assayed in Xenopus (frog) egg extracts,
which support replication licensing. The RL5 family of 2-arylqui-
nolin-4-amines also had strong inhibitory activity against replica-
tion licensing in the Xenopus system.
We used our knowledge of the licensing reaction in Xenopus
egg extract to determine the precise target of RL5a, the most
potent of the RL5 compounds. Licensing involves the sequential
DNA loading of the pre-replicative complex proteins ORC, Cdc6,
and Cdt1, which act together to clamp double hexamers of
MCM2–7 around DNA (Chong et al., 1995; Gillespie et al.,
2001; Evrin et al., 2009; Remus et al., 2009; Gambus et al.,
2011). Once MCM2–7 have been clamped around DNA ORC,
Cdc6, and Cdt1 are no longer required to maintain the licensed
state (Hua and Newport, 1998; Rowles et al., 1999). It has previ-
ously been shown in Xenopus egg extract, S. cerevisiae, and
C. elegans early embryos that an initial tight binding of ORC
andCdc6 to DNA is relaxed once licensing has occurred (Rowles
et al., 1999; Oehlmann et al., 2004; Tsakraklides and Bell, 2010;
Sonneville et al., 2012). This is thought to allow the recycling of
ORC, Cdc6, and Cdt1 so that these proteins can each load mul-
tiple MCM2–7 double hexamers and thereby license multiple
origins.
We show that RL5a inhibits ORC by preventing it forming a
tight complex with DNA that is required for origin licensing.
When licensing was blocked by other means—by depleting ex-
tracts of MCM2–7 or Cdc6, or by addition of the Cdt1 inhibitor
geminin—RL5a blocked the formation of a salt-resistant interac-
tion of ORC with DNA. However, RL5a did not inhibit the weak
association of ORC that occurs after origins have been licensed.
RL5a inhibits the binding of ORC to DNA in both (physiological)
chromatin templates and naked DNA. We therefore conclude
that RL5a blocks origin licensing by selectively blocking the
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formation of a tight ORC-DNA complex, which is a pre-requisite
for the licensing reaction to occur (Figure 7B).
ORC is an ATPase and its tight binding to origin DNA depends
on ATP (Bell and Stillman, 1992; Klemm et al., 1997; Gillespie
et al., 2001; Bowers et al., 2004; Randell et al., 2006; Li and Still-
man, 2012). The ATPase activity of Cdc6 and MCM2–7 are also
involved in driving the licensing reaction and in recycling ORC
and Cdc6 (Zwerschke et al., 1994; Evrin et al., 2013; Frigola
et al., 2013; Coster et al., 2014; Evrin et al., 2014; Kang et al.,
2014; Chang et al., 2015). We show here that in Xenopus egg
extract, the formation of a tight interaction between ORC and
DNA is dependent on ATP or non-hydrolyzable ATP-g-S (Fig-
ure 7Bi and Bii). Under normal circumstances ATP hydrolysis
then occurs, which is accompanied by the loading of MCM2–7
double hexamers onto DNA and destabilization of the interaction
between ORC and DNA (Chang et al., 2015; Coster et al., 2014;
Evrin et al., 2013; Frigola et al., 2013; Kang et al., 2014; Bowers
et al., 2004; Randell et al., 2006) (Figure 7Biii and Biv). ORC can
be kept tightly bound to DNA by preventing ATP hydrolysis (Gil-
lespie et al., 2001; Bowers et al., 2004; Randell et al., 2006; Evrin
et al., 2013).
We show that RL5a destabilizes the interaction between
ORC and DNA even if licensing is blocked by geminin or by the
replacement of ATP with non-hydrolyzable ATP-g-S. RL5a
therefore makes ORC behave as though it does not have access
to ATP and cannot form a tight complex with DNA. We therefore
examined whether RL5a may act as a competitive inhibitor for
ATP with respect to the licensing reaction. We showed that the
licensing reaction in Xenopus egg extract has an apparent KM
for ATP of 0.6 mM. In the presence of RL5a, the apparent KM
for ATP only increased slightly to 0.8 mM, suggesting that
RL5a does not have a strong ability to compete with ATP in
this reaction. Instead, these experiments suggest that RL5a
acts non-competitively with respect to ATP and can inhibit the
activity of ORC allosterically.
The RL5 family of compounds showed reasonable specificity
for inhibition of the licensing system. In Xenopus egg extracts
many nuclear processes occur normally in the presence of con-
centrations that strongly inhibit licensing. However, at higher
concentrations we detected a number of quite severe effects
of RL5a that were not mediated by its inhibition of ORC. In
U2OS cells, progression through mitosis occurred in the pres-
ence of 200 mM RL5 compounds, although progression through
S phase following release from a double-thymidine synchroni-
zation was retarded. All members of the RL5 family that had
anti-licensing activity also displayed these non-specific effects
(data not shown). RL5a does, however, have attractive physical
properties from a chemical tool or drug discovery perspective,
as it is small (molecular weight 281) and relatively polar (logD =
1.8). Furthermore, it showed selective inhibition of proliferation
of U2OS cancer cells when compared with primary IMR90 cells.
While providing a valuable tool to study replication licensing, an-
alogs of RL5a will need to more selectively inhibit replication
licensing if they are to be therapeutically useful.
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Figure 7. Depiction of the Licensing Reaction and Its Inhibition
by RL5a
(A)U2OSand IMR90cellswere incubated in 1, 2, 5, 10, 20, 50, or 100mMRL5aor
DMSO for either 24, 48, 72, 96, or 120 hr and the relative cell number determined.
Each data point presented is the mean ± SEM of three biological repeats each
formed from three technical repeats.
(B) (i) ORC initially binds weakly to DNA. (ii) In the presence of ATP or ATP-g-S,
ORC can bind tightly to DNA. This transition is inhibited by RL5a. (iii) Tightly
bound ORC further recruits Cdc6 and Cdt1 to DNA. (iv) Double hexamers
of MCM2–7 are clamped around DNA as the origin becomes licensed. This
requires ATP hydrolysis.
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SIGNIFICANCE
During S phase of the eukaryotic cell division cycle,
pairs of replication forks are initiated at replication origins
distributed throughout the genome. Replicative helicase
function is provided by activated hexamers of the mini-
chromosome maintenance proteins, MCM2–7, which un-
wind DNA at the head of the replication fork. In late mitosis
and G1, future origins of DNA replication are ‘‘licensed’’
for use in the upcoming S phase by being encircled by
inactive double hexamers of MCM2–7. To facilitate com-
plete genome duplication during S phase, a ‘‘licensing
checkpoint’’ exists to ensure that only cells with a suffi-
cient number of licensed origins progress into S phase.
Importantly, the licensing checkpoint is defective in many
cancer cells, due to the involvement in checkpoint activity
of p53, pRb, and p21Cip1, which are mutated or ineffec-
tive in many cancers. Whereas normal cells will reversibly
arrest in G1 following licensing inhibition, cancer cells
lacking the checkpoint will enter an abortive S phase.
Inhibition of licensing can therefore selectively kill cancer
cells. This makes the licensing system an attractive anti-
cancer target with a potentially high therapeutic index for
many different sorts of cancers. We describe here a high-
throughput cell-based screen for inhibitors of replication
licensing with which we identified a family of 2-arylquino-
lin-4-amines, the most potent of which we call RL5a.
The loading of MCM2–7 onto DNA requires the activity of
three additional licensing factors: the origin recognition
complex (ORC), which binds origin DNA, Cdc6, and Cdt1.
We show that RL5a prevents ORC forming a tight complex
with DNA that is required for MCM2–7 loading. Further-
more, we show that the proliferation of cells lacking the
licensing checkpoint is more sensitive to RL5a than those
in which it is intact. This study presents the first descrip-
tion of small-molecule inhibitors of replication licensing
that have anti-cancer potential.
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STAR+METHODS
KEY RESOURCES TABLE
CONTACT FOR REAGENT AND RESOURCE SHARING
Requests for resources, reagents and further information should be directed to and will be fulfilled by, the Lead Contact, J. Julian
Blow (j.j.blow@dundee.ac.uk).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Xenopus laevis
Wild type, sexually mature (R 1 year old) female and male South African Clawed frogs (Xenopus laevis) born and reared in the UK
(University of Plymouth) were used in this study for the production of unfertilised eggs (from which extracts were prepared) and
sperm, respectively. Frogs were maintained at 19C in particulate filtered, dechlorinated water, at a density of %15 animals per
60 L tank, in a purpose built ‘‘aquacentre’’ and were maintained by a professional staff at the University of Dundee adhering to
Home Office (UK Government) animal husbandry guidelines; the animals have access to a Home Office (UK Government) approved
veterinary surgeon. The frogs were fed a vegetable and fish based diet (Aquatic Diets 3, Mazuri Zoo Foods) 2-3 times per week, as
required.
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Alexa Fluor 488 goat anti-mouse antibody Invitrogen A11029; RRID: AB_138404
Alexa Fluor 488 goat anti-rabbit antibody Invitrogen A11034; RRID: AB_2576217
Mcm2 (BM28) primary antibody BD Biosciences 610701; RRID: AB_398024
Mcm3 primary antibody N/A Prokhorova and Blow, 2000
Mcm4 primary antibody Santa Cruz Sc22779; RRID: AB_2142394
Mcm5 primary antibody Santa Cruz Sc136366; RRID: AB_10647089
Mcm7 primary antibody N/A Prokhorova and Blow, 2000
Orc1 primary antibody N/A Rowles et al., 1996
Orc2 primary antibody N/A Oehlmann et al., 2004
Cdc6 primary antibody N/A Oehlmann et al., 2004
Cdt1 primary antibody N/A Tada et al., 2001
Lamin B1 primary antibody Abcam 16048; RRID: AB_443298
a-Tubulin primary antibody Sigma-Aldrich T6199; RRID: AB_477583
Chemicals, Peptides, and Recombinant Proteins
Thymidine Sigma T1895
RO3306 Alexis ALX-270-463
RL5a Maybridge 198-004-017
RL5b Maybridge 198-004-023
RL5c Maybridge 198-004-021
Apyrase Sigma A6410
Critical Commercial Assays
Click-iT Plus EdU Alexa Fluor 647 Flow Cytometry Assay Kit Invitrogen C10634
PrestoBlue Cell Viability Reagent Invitrogen A13262
Experimental Models: Cell Lines
U2OS cells ATCC HTB-96, Lot 7658494
IMR90 cells ATCC CCL-186, Lot 62162583
Experimental Models: Organisms/Strains
Wild type Xenopus laevis (male and female) University of Plymouth, UK N/A
Cell Chemical Biology 24, 981–992.e1–e4, August 17, 2017 e1
Cell Lines
U2OS cells (Female; ATCC, Cat. No. HTB-96, Lot 7658494) and IMR90 cells (Female; ATCC, Cat. No. CCL-186, Lot 62162583) were
grown in DMEM (Invitrogen, Cat No.12491-023) supplemented with 10% FBS (Invitrogen) plus 100U/ml penicillin, 100 mg/ml strep-
tomycin (Invitrogen, Cat. No.15070-063) at 37C with 5% CO2.
METHOD DETAILS
Flow Cytometry
3D Flow Cytometry was performed as described (Moreno et al., 2016). Cells were treated with 40 mMEdU (Invitrogen) for 30 min prior
to trypsinization and collection. Cells were pre-extracted with CSK buffer (10mM HEPES pH 7.4, 300 mM Sucrose, 100 mM NaCl,
3 mM MgCl2, 0.5% Triton-X-100) for 10 min on ice and then fixed in 2% formaldehyde for 15 min. Cells were permeabilised in
ice-cold 70% ethanol for 10 min and incubated for 1 hr with anti-BM28 (MCM2) primary antibody (1:500) (BD Biosciences, Cat.
No. 610701). After staining with Alexa Fluor 488 goat anti-mouse antibody (Invitrogen, Cat. No. A11029) cells were washed and
the Click-it EdU reaction (Invitrogen, Cat. No. C10634) was performed for 30 min. Finally, cells were treated with propidium Iodide
(PI) solution (50 mg/ml PI, 50 mg/ml RNaseA, 0.1% Triton-X-100) and transferred to FACS tubes for analysis. Cells analysed for their
DNA content only were fixed and treated with PI as above. All samples were acquired using a BD FACSCanto and results analysed
using FlowJo software.
Cell-based Compound Screen
U2OS cells were synchronized at the G1/S border using a double thymidine block (1 mM thymidine; Sigma, Cat. No. T1895; 16 hr for
the first block followed by release for 12 hr and a second block for 18 hr); cells were then seeded onto 384-well plates in the absence
of thymidine and 6 hr later were blocked at the G2/M border by addition of 9 mMRO3306 (Alexis, Cat. No. ALX-270-463, stock made
up at 9 mM in dimethyl sulphoxide). After a further 10 hr, cells were released from RO3306 inhibition, washed and then compound
added. After incubation for 8 hr the plates were removed to a Janus Automated Workstation where the wells were washed 3 times in
PBS. The cells were then extracted with the addition of ice-cold CSK buffer containing 0.3% Triton-X100 (CSK: 10 mM Hepes-KOH
pH 7.4, 300 mM sucrose, 100 mM NaCl, 3 mM MgCl2) for 10 min at RT to remove non-chromatin bound Mcms. Wells were then
washed once with PBS 0.1% Triton-X100 and then fixed by the addition of -20C methanol for 5 min. Cells were then washed twice
with PBS 0.1% Triton, once with PBS and then were either processed immediately for staining or stored in PBS overnight at 4C.
Plates were then probed with 1: 50 Mcm4 primary antibody (Santa Cruz, Cat. No. Sc22779) followed by 1:300 Alexa Fluor 488
goat anti-rabbit antibody (Invitrogen, Cat. No. A11034) and DAPI (Sigma, Cat. No. D9564).
Microscopic images (6 fields / well) of each treatment were taken on an InCell 1000 system (GE healthcare) using a 20x objective.
ActivityBase from ID Business Solutions was used for the data processing and analysis, returning values for Mcm4 and DNA content
for each of the cells identified. Figure S6 details the platemaps used for the assay. AQuality Control plate was included for every three
assay plates (Figure S6), where columns 1-12 were low control wells (+ R03306 + 1% DMSO) and columns 13-24 were high control
well (+Media + 1%DMSO). The performance of the assay on each screening plate was evaluated using internal controls. The criteria
for data acceptance of an assay plate were signal to background (mean Hi Control) / (mean Lo Control) >1.5; Z-prime (1 - (3 x Lo
Control Standard Deviation + 3 x SD Hi Control Standard Deviation) / (mean Hi Control - mean Lo Control)) >0.3. The statistics
from all assay plates and Quality Control plates were analysed. The screen performance indicators were: signal to background
2.4±0.53 and Z-prime 0.47±0.10.
For the secondary screen, mitotic cells were acquired by shake-off from asynchronous cell cultures, spun and re-plated into
the test compounds for 2 hr before being processed as above. RL5a, RL5b and RL5c were purchased from Maybridge with product
codes 198-004-017, 198-004-023 and 198-004-021 respectively.
Cell Proliferation Assay
U2OS and IMR90 cells were grown in complete DMEM, as described. Cells, seeded in 96-well plates, were given 24 hr to adhere prior
to the addition of RL5a. At the indicated times, 5% (v/v) PrestoBlue Cell Viability Reagent (Invitrogen, Cat. No. A13262) was added to
each well and incubated for 1 hr. Fluorescence was quantified using a FLUOstar Omega plate reader (BMG Labtech) and measure-
ments taken at 544 nm excitation and 590 nm emission. The raw data was background corrected using a complete/supplemented
DMEM, DMSO and PrestoBlue blank well and normalised against cell number after 24 hr. Each datapoint presented is the mean of 3
biological repeats each formed from 3 technical repeats.
Xenopus Egg Extracts
Metaphase-arrested Xenopus laevis egg extract and demembranated Xenopus sperm nuclei were prepared as described (Gillespie
et al., 2012, 2016).
Female frogs were primed with 150 units of Folligon (Pregnant Mare Serum Gonadotrophin) 3 days before the eggs were required
to increase the number of stage 6 mature oocytes and 2 days later, were injected with 500 units Chorulon (Chorionic Gonadotrophin)
to induce ovulation. Frogswere placed in individual laying tanks at 18-21C in 2 l 1xMMRegg laying buffer, prepared from a 10x stock
(1 M NaCl, 20 mM KCl, 10 mMMgCl2, 20 mM CaCl2,1 mM EDTA, 50 mM HEPES-NaOH, pH 7.8). The following morning, eggs were
collected and rinsed in 1x MMR to remove any non-egg debris. Washed eggs were dejellied in 2% w/v cysteine (pH 7.8), washed in
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XBE2 (1x XB salts, 1.71% w:v sucrose, 5 mM K-EGTA, 10 mM HEPES-KOH, pH 7.7; 10x XB salts: 2 M KCl, 40 mM MgCl2, 2 mM
CaCl2) and then into XBE2 containing 10 mg/ml leupeptin, pepstatin and aprotinin. Dejellied and washed eggs were centrifuged in
14ml tubes, containing 1ml XBE2 plus protease inhibitors containing 100 mg/ml cytochalasin D, at 1400 x g in a swinging bucket rotor
for 1 min at 16C to pack the eggs, after which excess buffer and dead eggs were removed. Packed eggs were crushed by centri-
fugation at 16,000 x g in a swinging bucket rotor for 10 min at 16C. The dirty brown cytoplasmic layer was collected using a 20G
needle and a 1 ml syringe via side puncture. From this point onwards the extract was kept on ice. The crude extract was supple-
mented with cytochalasin D, leupeptin, pepstatin and aprotinin all to a final concentration of 10 mg/ml, 1:80 dilution of energy regen-
erator (1 M phosphocreatine disodium salt, 600 mg/ml creatine phosphokinase in 10 mM HEPES-KOH pH 7.6) and 15% v:v LFB1/50
(10%w:v sucrose, 50mMKCl, 2 mMMgCl2, 1 mMEGTA, 2mMDTT, 20mMK2HPO4/KH2PO4 pH 8.0, 40mMHEPES-KOH, pH 8.0).
The extract was clarified by centrifugation at 84,000 x g in a pre-cooled SW55 rotor swinging bucket rotor at 4C for 20 min. The
golden cytoplasmic layer was recovered, supplemented with glycerol to 2% v/v and frozen in aliquots in liquid nitrogen and stored
at -80C until required.
Sperm was recovered from testes isolated from male frogs post mortem following a lethal dose of anaesthetic (0.2% w:v Tricaine
mesylate MS222, 0.5% w:v NaHCO3, to pH 7.5). Isolated testes were washed carefully to avoid bursting in EB (50 mM KCl, 5 mM
MgCl2, 2mMdithiothreitol or b-mercaptoethanol, 50mMHEPES-KOH, pH 7.6), prior to being finely choppedwith a clean razor blade
in fresh EB. Recovered lysate was filtered through a 25 mmnylon membrane to remove particulate matter. Filtered sperm was centri-
fuged at 2,000 x g at 4C for 5 min; selective resuspension of the sperm pellet allowed separation of the sperm from contaminating
erythrocytes; the resuspended sperm was respun and the pellet resuspended in 0.5 ml SuNaSp (0.25 M sucrose, 75 mM NaCl,
0.5 mM spermidine, 0.15 mM spermine, 15 mM HEPES-KOH, pH 7.6) per testis. The sperm was demembranated with the addition
of 25 ml per testis lysolecithin (5 mg/ml, in H2O) for 10 min at room temperature. Demembranated sperm were respun and resus-
pended in SuNaSp plus 3% w/v BSA to quench the demembranation reaction. Quenched sperm were respun and resuspended
in EB plus 30% glycerol per testis, counted using a haemocytometer and stored at -80C.
Extracts were supplemented with 250 mg/ml cycloheximide, 25 mM phosphocreatine and 15 mg/ml creatine phosphokinase and
incubated with 0.3 mMCaCl2 for 15minutes to trigger release frommetaphase arrest. For DNA synthesis reactions, demembranated
Xenopus sperm nuclei were incubated at 6-10 ng DNA/ml in extract. DNA synthesis was assayed by measuring incorporation of
[a-32P]dATP into acid-insoluble material followed by scintillation counting, as described (Gillespie et al., 2012, 2016). Extract was
supplemented with 50 nCi/ml [a-32P]dATP from a high activity 10 mCi/ml stock. At the appropriate times 10 ml aliquots were stopped
by the addition of 160 ml Stop-C (0.5%w:v SDS, 5mMEDTA, 20mMTris HCl, pH 7.5) plus freshly added 0.2mgml Proteinase K (from
a stock of 20 mg/ml proteinase K, 50% v:v glycerol, 10 mM Tris HCl, pH 7.5) and were incubated at 37C for 30 min. Samples are
precipitated at 4C for 30 min by the addition of 4 ml 10% TCA (10%w:v TCA, 2%w:v Na4P2O7.10H2O). 40 ml (1% of 4ml) of the total
reaction was spotted on a paper disc. Insoluble material was recovered from solution by filtration through a glass fibre filter mounted
on a vacuummanifold. The glass fibre filters were twice washed in 5% TCA (5%w:v TCA, 0.5%w:v Na4P2O7.10H2O), once in 100%
ethanol and then air dried. The paper and glass fibre filters were then quantified by scintillation counting. Precipitated material was
expressed as a percentage of total counts (%TC) from which DNA replication (ng/ml) was calculated by multiplying by a factor of
0.654. The extent of nuclear formation was followed under the light microscope (phase contrast). All incubations were carried out
at 23C.
Licensing factor extract (LFE) was prepared as described (Chong et al., 1997). The initial steps for preparing metaphase extracts
were followed. Before the final spin the extract was activated with 0.3 mM CaCl2 for 15 minutes then diluted 5 fold with ‘‘Licensing
Factor Buffer’’ (LFB: 40 mM Hepes KOH pH 8.0, 20 mM K2HPO4/ KH2PO4 pH 8.0, 2 mMMgCl2, 1 mM EGTA, 2 mM DTT, 10% (w/v)
sucrose and 1 mg/ml each of leupeptin, pepstatin and aprotinin) supplemented with 50 mM KCl (i.e. LFB1/50) and spun to remove
membrane components at 84,000 x g in a pre-cooled SW55 rotor swinging bucket rotor at 4C for 40 min. The clarified supernatant
was frozen, in aliquots, in liquid nitrogen and stored at -80C till required.
Extracts immunodepleted for either ORC or Cdc6 were prepared as described (Chong et al., 1997). Briefly, rProtein A agarose
beads (GEHC), preincubated with 2 volumes of either anti-Orc1 or anti-Cdc6 serum, were twice incubated with interphase whole
egg extract at a ratio of 1 volume extract plus 0.7 volume beads. Twice depleted extract, recovered from the beads, was frozen
in aliquots in liquid nitrogen and stored at -80C.
Desalted & Apyrase Treated Extracts
Desalted interphase extract was prepared as described (Gillespie et al., 2001), except that that reaction was scaled up and a PD-10
desalting column (GEHC) was used, as permanufacturer’s instructions. Briefly, the columnwas first equilibrated in LFB1/50. 600 ml of
metaphase arrested extract, supplemented with only cycloheximide was released into interphase with 0.3 mM CaCl2 for 15 min at
23C. Activated extract was applied to the column under gravity and after this had completely entered into the resin bed, 2.3 ml of
buffer was then applied; all washes and eluates up to and including this stage were discarded. Following this a further 2.4 ml of buffer
was applied to the column and the eluate, containing the peak of protein elution, was collected, pooled, frozen in Eppendorf tubes in
liquid nitrogen in appropriate aliquots and stored at -80C. The final extract recovered was diluted 4-fold. All column steps were
undertaken at 4C.
To prepare Apyrase treated extract, metaphase extract supplemented with only cycloheximide was first released into interphase
with 0.3 mM CaCl2 for 5 min at 23
C. Following this, the activated extract was treated with 0.01 U/ml of Apyrase (Sigma, Cat. No.
A6410) for 10 mins at 23C prior to sperm addition.
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Chromatin Isolation
Chromatin isolation and immunoblotting fromU20S cells were performed using standard techniques (Moreno et al., 2016); extraction
of the chromatin-bound fraction was performed by treatment with CSK extraction buffer (10 mM Hepes, pH 7.4, 300 mM sucrose,
100 mM NaCl, 3 mM MgCl2, and 0.5% Triton-X-100) for 10 min on ice. The pellet, containing chromatin-associated proteins, was
processed for immunoblotting. All chromatin isolations from Xenopus egg extracts performed using either whole, immunodepleted,
desalted or apyrase treated extracts were undertaken in low adhesive Eppendorf tubes, as described (Gillespie et al., 2012, 2016).
Briefly, reactions were stopped by the addition of 400 ml of ice-cold NIBTX (50 mM KCl, 50 mM Hepes KOH pH 7.6, 5 mM MgCl2,
2 mM DDT, 0.5 mM spermidine 3HCl, 0.15 mM spermine 4HCl, 0.1% Triton X-100). This was underlayered with 100 ml 15% sucrose
in NIBTX. The tubes were spun at 6000 x g for 5 min at 4C in a swinging bucket rotor. The buffer above the sucrose cushion was
removed and the surface of the cushion washed with 200 ml NIBTX before removing the cushion down to  15 ml. The tubes were
then spun at 13000 x g for 2 min to focus the chromatin pellet and following this, all the buffer was removed. The chromatin pellet
was then resuspended in loading buffer andwas subjected to immunoblotting by standard techniques using 4–12%Bis-Tris gradient
SDS–PAGE gels (Invitrogen) and enhanced chemiluminescence (ECL) detection (SuperSignal West Pico Chemiluminescent). Images
were captured using either standard X-ray film or an ImageQuant LAS4000 (Fujifilm) CCD camera imager and CCD camera images
were quantified using ImageStudioLite (Licor) software. The total protein content of chromatin was determined by subjecting samples
isolated in NIBTX prepared with an additional 20 mM KCl over a 30% sucrose cushion and spun at 6000 x g for 5 min at 4C in a
swinging bucket rotor, to SDS-PAGE and visualising resolved polypeptides by SYPRO-Ruby staining.
The plasmid DNA binding assay was performed as described (Harvey and Newport, 2003) using pET28 as the template. Plasmid
samples were diluted in 2 ml of ELB (50mMKCl, 2.5 mMMgCl2, 10mMHEPES pH 7.7, 250mM sucrose) with 0.2 mMATP and 0.5%
Triton X-100, and centrifuged in a pre-cooled SW55 swinging bucket rotor at 100,0003 g at 4C for 10 min. Chromatin pellets were
washed once in ELB-ATP-Triton X-100 and respun. Isolated samples were subjected to SDS-PAGE and immunoblotting and a pro-
portion was run on an EtBr stained 1% agarose gel in 0.5x TBE to assess DNA recovery. Partially purified fractions of ORC were pre-
pared by precipitation of LFE with 4.25% PEG and were resuspended in LFB1/50 supplemented with 2.5 mM ATP (Gillespie
et al., 2001).
Antibodies and Recombinant Protein
Antibodies used for immunoblotting were: anti-Orc1 (Rowles et al., 1996), -Orc2 & -Cdc6 (Oehlmann et al., 2004), -Cdt1 (Tada
et al., 2001), -Mcm3 and 7 (Prokhorova and Blow, 2000), -hMCM2 (BM28) (610701; BD Biosciences), -hMCM5 (Sc136366; Santa
Cruz), -Lamin B1 (16048; Abcam) and -a-Tubulin (T6199; Sigma-Aldrich). Recombinant geminin-DEL was a gift from Andrew Feren-
bach (Ferenbach et al., 2005).
Polyethylene Glycol Precipitation
ATP-depleted extracts were prepared from LFE by precipitating with 16% (w/v) PEG6000 (using a stock 50% (w/v) PEG solu-
tion), incubated on ice for 30 min, and centrifuged a 12,000 x g for 10 min in a fixed-angle rotor. The pellet was resuspended in
LFB1/50 at 0.4X and refrozen till required.
Licensing Assay
Licensing assays were performed essentially as described (Chong et al., 1997). Briefly, sperm were first incubated in drug treated
interphase extract for 15 min at 23C, during which time the DNA has the opportunity to be licensed. 2 volumes of interphase extract
containing an excess of geminin-DEL (McGarry and Kirschner, 1998; Tada et al., 2001) and [a-32P]dATP was then added to the
samples. The geminin prevents any further licensing. The extracts were then incubated at 23C for 90 min to allow DNA replication
to be driven by origins licensed in the previous step.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical data for individual experiments are presented in the appropriate figure legends. In all cases ‘‘n’’ is the number of indepen-
dent experimental repeats from which the mean ±S.E.M. has been calculated.
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